Does geographical location influence the phenotype of fabry disease in women in Europe?

Clinical Genetics

Volumn 77, Issue 2, 2010, Pages 131-140

  Barba Romero, M Á ^a   Deegan, P ^b   Giugliani, R ^c   Hughes, D ^d  

^a University Hospital   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Fabry disease; Fabry outcome survey; FOS MSSI score; Phenotype

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPIGENETICS; EUROPE; FABRY DISEASE; FEMALE; FOOD INTAKE; GEOGRAPHY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; NONSENSE MUTATION; ONSET AGE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE;

ADULT; AGE FACTORS; ALPHA-GALACTOSIDASE; DIET, MEDITERRANEAN; EPIGENESIS, GENETIC; EUROPE; FABRY DISEASE; FEMALE; GEOGRAPHY; HUMANS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 73949141493     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01345.x     Document Type: Article

References (44)

1. Desnick RJ, Ioannou YA, Eng CM, Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease 2001, 3733-3774. α-Galactosidase A deficiency: Fabry disease. In, eds., 8th edn, New York, NY, McGraw-Hill
2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001, 38:769-775.
3. Whybra C, Kampmann C, Willers I. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001, 24:715-724.
4. Deegan PB, Baehner AF, Barba Romero M- thomampersan. Natural History of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006, 43:347-352.
5. Wang RY, Lelis A, Mirocha J. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007, 9:34-45.
6. Street NJ, Yi MS, Bailey LA. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population and patients with other chronic disease. Genet Med 2006, 8:346-353.
7. Wilcox WR, Oliveira JP, Hopkin RJ. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008, 93:112-128.
8. Schiffmann R, Warnock DG, Banikazemi M. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009, 24:2102-2111.
9. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961, 190:372-373.
10. Dobyns WB, Filauro A, Tomson BN. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A 2004, 129:136-143.
11. Meikle PJ, Hopwood JJ, Clague AE. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
12. Spada M, Pagliardini S, Yasuda M. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006, 79:31-40.
13. Risch N, Tang H, Katzenstein H. Geographic distribution of disease mutations in the Ashkinazi Jewish population supports genetic drift over selection. Am J Hum Genet 2003, 72:812-822.
14. Menotti A, Lanti M, Puddu PE. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000, 84:238-244.
15. Conroy RM, Pyörälä K, Fitzgerald AP. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
16. Mehta A, Ricci R, Widmer U. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004, 34:236-242.
17. Mehta A, Beck M, Sunder-Plassmann G. Fabry disease: perspectives from 5 years of FOS. 2006, eds., Oxford, Oxford PharmaGenesis
18. Levey AS. Clinical practice. Nondiabetic kidney disease. N Eng J Med 2002, 347:1505-1511.
19. Devereux RB, Alonso DR, Lutas EM. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
20. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994, 23:129-138.
21. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group
22. Whybra C, Kampmann C, Krummenauer F. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004, 65:299-307.
23. Altarescu G, Moore DF, Pursley R. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001, 32:1559-1562.
24. Igarashi T, Sakuraba H, Suzuki Y. Activation of platelet function in Fabry disease. Am J Hematol 1986, 22:63-67.
25. DeGraba T, Azhar S, Dignat-George F. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000, 47:229-233.
26. Kanel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002, 5:27-37.
27. O'Neill ES, Morrow EL. The symptom experience of women with chronic illness. J Adv Nurs 2001, 33:257-268.
28. Ladwig HK, Marte-Mittay B, Formanek B. Gender differences of symptom reporting and medical health care utilization in the German population. Eur J Epidemiol 2000, 16:511-518.
29. Verbrugge LM, Wingard DL. Sex differentials in health and mortality. Women Health 1982, 12:103-145.
30. Jürges H. True health vs response styles: exploring cross-country differences in self reported health. Health Econ 2007, 16:163-178.
31. World Development Indicators database [database on the Internet]. http://siteresources.worldbank.org/DATASTATISTICS/Resources/GDP.pdf, The World Bank, [Revised 10 September 2008; accessed January 28, 2009]. Available from
32. United Nations development reports [database on the Internet]. The human development index 2007/2008. http://hdr.undp.org/en/media/HDR_20072008_Table_1.pdf, United Nations, [accessed January 28, 2009]. Available from
33. United Nations development reports [database on the Internet]. The gender-related development index. http://hdr.undp.org/en/media/HDR_20072008_GDI.pdf, United Nations, [accessed January 28, 2009]. Available from
34. Happle R. X-chromosome inactivation: role in skin disease expression. Acta Paediatr 2006, 95((Suppl. 451)):16-23.
35. Sharp A, Robinson D, Jacobs P. Age- and tissue-specific variation of X-chromosome inactivation ratios in normal women. Hum Genet 2000, 107:343-349.
36. Gale RE, Fielding AK, Harrison CN. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 1997, 98:512-519.
37. Dobrovolny R, Dvorakova L, Ledvinova J. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 2005, 83:647-654.
38. Maier EM, Osterrieder S, Whybra C. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr 2006, 95(Suppl. 451):30-38.
39. Sofi F, Cesari F, Abbate R. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008, 337:a1344.
40. Anderson JW, Baird P, Davis RH. Health benefits of dietary fiber. Nutr Rev 2009, 67:188-205.
41. Kaye EM, Kolodny EH, Logigian EL. Nervous system involvement in Fabry disease: clinicopathological and biochemical correlation. Ann Neurol 1988, 23:505-509.
42. Health and food. Special Eurobarometer 246/wave 64.3-TNS Opinion & Social. 2006, http://ec.europa.eu/health/ph_publication/eb_food_eh.pdf, European Commission, Accessed September 2009, from
43. Altarescu G, Chicco G, Whybra C. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP level with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis 2008, 31:117-123.
44. Lopez-Garcia E, Schulze MB, Fung TT. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004, 80:1029-1035.